HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jie Mu Selected Research

Jie Mu Research Topics

Disease

5Epilepsy (Aura)
01/2024 - 10/2012
4Inflammation (Inflammations)
04/2023 - 07/2019
3Seizures (Absence Seizure)
01/2024 - 01/2017
3Non-alcoholic Fatty Liver Disease
01/2023 - 04/2017
2Neoplasms (Cancer)
01/2022 - 01/2021
2Sepsis (Septicemia)
11/2017 - 10/2017
2Body Weight (Weight, Body)
04/2017 - 10/2012
1Developmental Dysplasia of the Hip
12/2023
1Contracture
12/2023
1Fibrosis (Cirrhosis)
10/2023
1Acquired Immunodeficiency Syndrome (AIDS)
03/2023
1COVID-19
01/2023
1Focal Cortical Dysplasia
01/2023
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2023
1Liver Diseases (Liver Disease)
01/2023
1Accidental Injuries
01/2022
1Myocardial Infarction
01/2022
1Coronary Disease (Coronary Heart Disease)
01/2022
1Hyperalgesia
01/2022
1Prostatic Neoplasms (Prostate Cancer)
01/2022
1Pain (Aches)
01/2022
1Fever (Fevers)
07/2021
1Demyelinating Diseases (Demyelinating Disease)
07/2021
1Nervous System Diseases (Neurological Disorders)
07/2021
1Wounds and Injuries (Trauma)
02/2021
1Lymphatic Metastasis
01/2021
1Major Depressive Disorder (Major Depressive Disorders)
01/2021
1Hepatitis
01/2021
1Adenolymphoma
06/2020
1Pleomorphic Adenoma
06/2020
1Calculi (Calculus)
01/2020
1Ischemic Stroke
01/2020
1Respiratory Hypersensitivity
10/2019
1Pneumonia (Pneumonitis)
10/2019
1Hypoxia (Hypoxemia)
07/2019
1Rheumatoid Arthritis
02/2019
1Cognitive Dysfunction
10/2017
1Brain Diseases (Brain Disorder)
10/2017

Drug/Important Bio-Agent (IBA)

2Anticonvulsants (Antiepileptic Drugs)IBA
01/2024 - 01/2017
2LipidsIBA
04/2023 - 01/2023
2Proteins (Proteins, Gene)FDA Link
01/2023 - 01/2020
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2023 - 04/2017
2ChemokinesIBA
01/2022 - 01/2020
2Phenobarbital (Luminal)FDA Link
01/2022 - 01/2016
2QingkailingIBA
01/2021 - 01/2020
2geniposideIBA
01/2020 - 07/2019
2NF-kappa B (NF-kB)IBA
01/2020 - 01/2020
2TOR Serine-Threonine KinasesIBA
11/2017 - 10/2017
1Indicators and Reagents (Reagents)IBA
01/2024
1Monoclonal AntibodiesIBA
10/2023
1TNF Receptor-Associated Factor 2 (TRAF2)IBA
04/2023
1Lysergic Acid Diethylamide (LSD)IBA
03/2023
1Biomarkers (Surrogate Marker)IBA
03/2023
1xiaoyaoIBA
01/2023
1Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
01/2023
1Circular RNAIBA
01/2023
1Therapeutic UsesIBA
01/2023
1Morphine (MS Contin)FDA LinkGeneric
01/2022
1Prostate-Specific Antigen (Semenogelase)IBA
01/2022
1Opioid Analgesics (Opioids)IBA
01/2022
1perampanelIBA
01/2022
1Androgen Receptors (Androgen Receptor)IBA
01/2022
1Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA
01/2022
1VaccinesIBA
07/2021
1CM 2-3IBA
02/2021
1chaihu-shugan-sanIBA
01/2021
1platinum-metallothionein complex (PT-MT)IBA
06/2020
1hyodeoxycholic acidIBA
01/2020
1Simvastatin (Zocor)FDA LinkGeneric
01/2020
1Cholic AcidIBA
01/2020
1Transforming Growth Factor beta (TGF-beta)IBA
01/2020
1NLR ProteinsIBA
01/2020
1Silicon Dioxide (Silica)FDA LinkGeneric
01/2020
1PowdersIBA
01/2020
1Nerve Growth Factors (Neurotrophins)IBA
01/2020
1Estrogens (Estrogen)FDA Link
01/2020
1niuhuangIBA
01/2020
1baicalinIBA
01/2020
1Toll-Like Receptors (Toll-Like Receptor)IBA
01/2020
1Interleukin-6 (Interleukin 6)IBA
01/2020
1AllergensIBA
10/2019
1Tight Junction ProteinsIBA
07/2019
170-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)IBA
11/2017
1Sirolimus (Rapamycin)FDA Link
10/2017
1shigyaku-san (Si-Ni-San)IBA
04/2017
1LDL Lipoproteins (beta Lipoproteins)IBA
04/2017

Therapy/Procedure

4Therapeutics
01/2023 - 10/2012
2Chinese Traditional Medicine (Traditional Chinese Medicine)
03/2023 - 04/2017
2Lasers (Laser)
01/2023 - 02/2021
1Reoperation
12/2023
1Hip Replacement Arthroplasty (Total Hip Replacement)
12/2023
1Transplantation
10/2023
1Highly Active Antiretroviral Therapy (HAART)
03/2023
1Electrocoagulation (Electrocautery)
01/2023
1Castration
01/2022
1First Aid (Aids, First)
01/2022
1Immunotherapy
01/2022
1Nursing Care
01/2022
1Lymph Node Excision (Lymph Node Dissection)
01/2021
1Neck Dissection (Radical Neck Dissection)
01/2021